{
    "Trade/Device Name(s)": [
        "WaveSense JAZZ\u2122 Blood Glucose Monitoring System",
        "AgaMatrix JAZZ\u2122 Blood Glucose Meter",
        "AgaMatrix JAZZ\u2122 Blood Glucose Test Strips",
        "AgaMatrix JAZZ\u2122 Control Solutions"
    ],
    "Submitter Information": "AgaMatrix, Inc.",
    "510(k) Number": "K072413",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW",
        "CGA",
        "JJX"
    ],
    "Summary Letter Date": "September 27, 2007",
    "Summary Letter Received Date": "August 28, 2007",
    "Submission Date": "August 27, 2007",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "WaveSense JAZZ\u2122 Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Meter",
        "Test Strips",
        "Control Solution"
    ],
    "Document Summary": "FDA 510(k) summary for AgaMatrix WaveSense JAZZ\u2122 Blood Glucose Monitoring System for quantitative glucose measurement in capillary whole blood",
    "Indications for Use Summary": "Indicated for quantitative measurement of glucose in fresh capillary whole blood from the fingertip, palm, or forearm for self-testing by persons with diabetes or for use in clinical settings by healthcare professionals to aid in monitoring diabetes control",
    "fda_folder": "Clinical Chemistry"
}